Friday 6 November 2026
Export OM’s income statement to Excel — free account
Outset Medical, Inc.
Outset Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $119.5 million, up 5.09% from fiscal 2024.
- Revenue
- +14.2%
- EPS
- +22.0%
- Free cash flow
- −61.9%
- Total debt
- +4.20%
Quarter to September 2026, against a year earlier
4.17
0.07
+1.71%
Follow OM
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.46 | 0.68 | 0.60 | 0.47 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.38) | (8.35) | (5.49) | (5.93) | |
P/B ratio |
0.67 | 0.83 | 0.63 | 0.44 | |
Price to Tangible BV |
0.67 | 0.83 | 0.63 | 0.44 | |
EV/Sales |
0.16 | 0.28 | 0.10 | (0.13) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.24 | |
EV/Operating CF |
(0.45) | (0.86) | (0.35) | 0.33 | |
EV/FCF |
(0.44) | (0.85) | (0.35) | 0.32 | |
Quick Ratio |
3.76 | 4.02 | 4.84 | 5.24 | |
Current Ratio |
4.86 | 5.19 | 6.29 | 6.67 | |
Net Debt/EBITDA |
11.40 | 3.14 | 3.61 | 4.21 | |
Debt/Assets |
0.00% | 40.76% | 38.88% | 36.39% | |
Debt/Equity |
0.00 | 1.03 | 0.87 | 0.76 | |
Asset Turnover |
0.48 | 0.44 | 0.43 | 0.44 | |
Operating CF/Net income |
0.71 | 0.54 | 0.68 | 0.49 | |
Capex/Depreciation |
(0.38) | (0.46) | (0.17) | (0.65) | |
Interest Coverage |
(3.50) | (4.55) | (5.02) | (5.12) | |
Research and Development Expense of Revenue |
17.56% | 17.23% | 20.16% | 17.51% | |
Selling, General and Administrative Expense of Revenue |
59.66% | 74.31% | 83.97% | 85.91% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.02% | 8.52% | 12.39% | 14.07% | |
Graham Net Nets |
1.24 | 1.02 | 1.40 | 2.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(129.00%) | (94.68%) | (108.33%) | (183.02%) | |
Free Cash Flow Yield |
(76.78%) | (48.34%) | (48.54%) | (83.51%) | |
Revenue per Share |
0.00 | 1.70 | 1.52 | 1.90 | |
Operating CF per Share |
0.00 | (0.52) | (0.70) | (0.63) | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.00 | (0.52) | (0.70) | (0.64) | |
Cash per Share |
0.00 | 7.91 | 8.53 | 11.11 | |
Shareholders Equity per Share |
0.00 | 5.17 | 6.08 | 8.35 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 5.17 | 6.08 | 8.35 | |
Free Cash Flow |
(10.49) | (9.75) | (12.91) | (9.74) | |
Working Capital |
171.77 | 183.96 | 199.10 | 213.25 | |
Capital Expenditures |
(0.11) | (0.11) | (0.06) | (0.22) | |
Net Current Asset Value |
69.13 | 81.80 | 98.94 | 113.34 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.23 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.68 | 32.06 | 31.11 | 31.97 | |
Average Payables |
3.01 | 2.95 | 1.31 | 2.21 | |
Average Inventory |
47.14 | 49.78 | 52.71 | 53.50 | |
Average Assets |
253.83 | 265.59 | 275.33 | 270.15 | |
Average Common Equity |
110.92 | 123.64 | 138.86 | 76.89 |
Columns are period end dates · fundamentals updated 4 Nov 2026